Innate Pharma S.A. (IPHA) vs MediWound (MDWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed MediWound (MDWD) over the past year, losing 22.1% versus a loss of 26.7%. Over five years, MDWD leads with a -46.2% price change compared with -74.1% for IPHA. Innate Pharma S.A. is the larger company by market cap ($169.8 million vs $165.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | MDWD |
|---|---|---|
| Share price | $1.52 | $12.85 |
| Market cap | $169.78M | $165.90M |
| 1-day change | -4.40% | -2.28% |
| YTD return | -13.14% | -30.39% |
| 1-year return | -22.05% | -26.74% |
| 5-year return | -74.11% | -46.17% |
| EPS (TTM) | $-0.59 | $-2.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $20.03 |
| 52-week low | $1.17 | $12.52 |
| Distance from 52-week high | -43.91% | -35.85% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +338.82% | +138.68% |
| Average volume | 156.71K | 84.01K |
| Shares outstanding | 111.70M | 12.91M |
| Employees | 120 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
IPHA vs MDWD FAQ
Which is bigger, Innate Pharma S.A. or MediWound?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $169.78M compared with $165.90M for MediWound (MDWD).
Which stock has performed better over the past year, IPHA or MDWD?
IPHA returned -22.05% over the past 12 months, compared with -26.74% for MDWD (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and MediWound in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Innate Pharma S.A. and Medicinal Chemicals and Botanical Products for MediWound.